Personalized medicine: An alternative for cancer treatment by Devendra Singh, Vinay Kumar Dhiman, Minakshi Pandey, Vivek Kumar Dhiman, Avinash Sharma, Himanshu Pandey, Sunil Kumar Verma, Rajeev Pandey

“…Prostate, colon, lung, and breast cancers are the most common types of cancer. In India, it is estimated that there will be around 2.7 million cancer patients by 2020. …”
Get full text

Alpelisib-Induced Diabetic Ketoacidosis and Insulin-Resistant Hyperglycemia by Michael Loke, DO, Vishal Sehgal, MD, Niraj Gupta, MD

“…Background/Objective: Alpelisib is a phosphatidylinositol 3-kinase inhibitor used to treat certain hormone therapy resistant breast cancers that can cause hyperglycemia through inhibition of the insulin signaling cascade. …”
Get full text

Single cell and spatial analysis of immune-hot and immune-cold tumours identifies fibroblast subtypes associated with distinct immunological niches and positive immunotherapy respo... by Benjamin H. Jenkins, Ian Tracy, Maria Fernanda S. D. Rodrigues, Melanie J. L. Smith, Begoña R. Martinez, Mark Edmond, Sangeetha Mahadevan, Anjali Rao, Hailing Zong, Kai Liu, Abhishek Aggarwal, Li Li, Lauri Diehl, Emma V. King, Jamie G. Bates, Christopher J. Hanley, Gareth J. Thomas

“…Pan-cancer analysis revealed several ‘iCAF’ subgroups present in both normal and cancer tissues; IL11 + iCAF were found in cancers from the gastrointestinal (GI) tract and transcriptomically distinct from iCAFs previously described in pancreatic and breast cancers with greater inflammatory properties; FRC-like fibroblasts were present at low frequencies in all tumour types, and were associated with significantly better survival in patients receiving checkpoint immunotherapy. …”
Get full text

Cancer mortality trends after implementation of the national programme for dispensarization of certain groups of the adult population: a population-based study from arkhangelsk, no... by L. E. Valkova, M. L. Levit, V. M. Merabishvili, A. Yu. Pankrateva, M. V. Krupina, D. M. Dubovichenko, A. V. Agaeva, A. Yu. Ryzhov, E. F. Potekhina, M. Yu. Valkov

“…Mortality rates “at working age” were low for all iMNs except for cervical and breast cancers and did not differ between periods; “premature mortality” decreased only in lung cancer in men from 40.1 to 36.2 per 100,000 population, with other iMNs differences between periods were not revealed. …”
Get full text